Compare VIPS & LGND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VIPS | LGND |
|---|---|---|
| Founded | 2008 | 1987 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.1B | 6.0B |
| IPO Year | 2012 | 1997 |
| Metric | VIPS | LGND |
|---|---|---|
| Price | $13.86 | $306.57 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 21 | 11 |
| Target Price | $16.08 | ★ $350.92 |
| AVG Volume (30 Days) | ★ 2.1M | 198.1K |
| Earning Date | 11-19-2026 | 10-29-2026 |
| Dividend Yield | ★ 4.44% | N/A |
| EPS Growth | N/A | ★ 2886.36 |
| EPS | N/A | ★ 0.31 |
| Revenue | N/A | ★ $141,102,000.00 |
| Revenue This Year | N/A | $8.68 |
| Revenue Next Year | $0.62 | $30.77 |
| P/E Ratio | ★ $9.00 | $1,019.77 |
| Revenue Growth | N/A | ★ 29.48 |
| 52 Week Low | $12.02 | $175.89 |
| 52 Week High | $20.49 | $326.63 |
| Indicator | VIPS | LGND |
|---|---|---|
| Relative Strength Index (RSI) | 65.72 | 50.10 |
| Support Level | $13.53 | $277.97 |
| Resistance Level | $14.14 | $318.30 |
| Average True Range (ATR) | 0.36 | 12.09 |
| MACD | 0.15 | -1.03 |
| Stochastic Oscillator | 86.65 | 30.44 |
Vipshop is a leading Chinese online discount retailer offering branded products at attractive discounts of 10%-90% off their original price through daily flash sales. It operates warehousing, retailing, product procurement, software development, and information technology support in-house while outsourcing to third-party logistics providers for distribution and shipments. Branded products on Vipshop's platform are sourced mostly through a consignment model with global brand partners. As of March 31, 2025, Eric Ya Shen, chair and CEO, had 64.5% voting rights. Leading Chinese social media firm and strategic shareholder Tencent also holds a 12.5% interest.
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.